Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease

NCT07604116 is registered in ClinicalTrials.gov with Synusight Biotech (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07604116
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07604116 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-Randomized, Open-Label Phase I Study to Evaluate the Safety, Tolerability, Biodistribution, Radiation Dosimetry, and Pharmacokinetics of SST001 in Healthy Volunteers, Patients With Multiple System Atrophy, and Patients With Parkinson's Disease
Lead sponsor
Synusight Biotech (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 15, 2026
Completion date
February 28, 2027
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy (msa), parkinson's disease (pd)